Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (Sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects With Low, Moderate, and Normal Sucrase Levels

NCT05480761 is registered in ClinicalTrials.gov with QOL Medical, LLC as lead sponsor.

NCT NCT05480761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05480761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (Sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects With Low, Moderate, and Normal Sucrase Levels
Lead sponsor
QOL Medical, LLC
Phase
Phase 4
Overall status
Terminated
Start date
August 1, 2022
Completion date
September 18, 2024
Enrollment
312 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

congenital sucrase-isomaltase deficiency, csid, sucrase isomaltase deficiency